- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.08. | Evaxion Cuts Quarterly Net Loss 23% While Maintaining Cash Runway Into Second Half Of 2027 | 1 | pulse2.com | ||
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 21.08. | Can Merck & Company (MRK)'s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery? | 16 | Insider Monkey | ||
| 20.08. | Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 20.08. | Evaxion reports Q2 results, plans cancer vaccine data presentation | 2 | Investing.com | ||
| 20.08. | Evaxion Biotech GAAP EPS of -$0.01 in-line | 2 | Seeking Alpha | ||
| 20.08. | Evaxion announces business update and second quarter 2026 financial results | 687 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business... ► Artikel lesen | |
| 17.08. | Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate | 1 | FierceBiotech | ||
| 17.08. | Boehringer Ingelheim übernimmt Evax | 9 | punkt4.info | ||
| 17.08. | Evaxion adds brain cancer vaccine to pipeline, discontinues EVX-03 | 3 | Investing.com | ||
| 17.08. | Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program | 367 | GlobeNewswire (Europe) | EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion's AI-Immunology platformGlioblastoma... ► Artikel lesen | |
| 17.08. | Boehringer übernimmt Schweizer Pferde-Biotech Evax | 4 | transkript.de | ||
| 14.08. | Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 | 704 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, will provide a business... ► Artikel lesen | |
| 14.08. | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.08. | Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG | 3.270 | GlobeNewswire (Europe) | Boehringer Ingelheim announced?today that it?has acquired?Evax AG,?a Swiss biotech company focused on equine health.
Founded more than a decade ago at the University of Zurich, Evax has been exploring... ► Artikel lesen | |
| 17.07. | Evaxion präsentiert auf ESMO-Kongress Dreijahresdaten zur Melanom-Studie mit EVX-01 | 2 | Investing.com Deutsch | ||
| 17.07. | Evaxion to present three-year EVX-01 melanoma trial data at ESMO | 1 | Investing.com | ||
| 17.07. | Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 | 589 | GlobeNewswire (Europe) | Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into... ► Artikel lesen | |
| 13.07. | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.07. | Evaxion presents preclinical data on AI-designed CMV vaccine | 1 | Investing.com | ||
| 12.07. | Evaxion presents preclinical data on CMV vaccine candidate | 1 | Investing.com |
1 2 3 4 5 Weiter >>
88 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,45 | +0,06 % | Zahlen stark, Bewertung billig: Zwar nicht BioNTech oder Moderna, aber auch dieses Unternehmen hat geliefert! | © Foto: Google GeminiZuletzt sorgten vor allem Biotechnologie-Werte für Schlagzeilen, doch auch klassische Pharmaunternehmen wie Dermapharm befinden sich in einer guten Verfassung Enthaltene Werte:... ► Artikel lesen | |
| EVOTEC | 3,246 | -3,05 % | BioTech: Übernahmen! Der Kampf um Marktanteile bei Novo Nordisk und Eli Lilly, BioNxt und Evotec auf dem M&A-Radar | Wie die jüngste, spektakuläre 43-Milliarden-USD-Übernahme des Krebsspezialisten Seagen durch Pfizer oder die Mega-Deals rund um die GLP-1-Infrastruktur eindrucksvoll zeigen, befindet sich die Pharmabranche... ► Artikel lesen | |
| QIAGEN | 37,235 | -0,94 % | QIAGEN profitiert von neuen Spekulationen: QIAGEN Aktie zieht wieder an Übernahmegespräche sorgen für frischen Rückenwind | Die QIAGEN Aktie erholt sich nach zwei schwächeren Handelstagen wieder. Neue Spekulationen über mögliche Übernahmegespräche sorgen am Markt für Kaufinteresse.Übernahmefantasie treibt den Kurs Die QIAGEN... ► Artikel lesen | |
| AMGEN | 369,50 | -0,15 % | Amgen's Repatha Reduces Risk Of Death In Patients At High Risk For A First Heart Attack Or Stroke | Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention... ► Artikel lesen | |
| NOVAVAX | 8,100 | +0,50 % | Novavax announces regulatory approvals for updated COVID shot | ||
| STRYKER | 279,00 | +0,07 % | Stryker to acquire ZuriMed to boost shoulder offerings | ||
| BIOGEN | 187,34 | +0,41 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,090 | +0,13 % | H.C. Wainwright bestätigt Kaufempfehlung für CRISPR Therapeutics Aktie | ||
| OCUGEN | 1,142 | 0,00 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| CLINUVEL | 5,002 | -0,91 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| DYNE THERAPEUTICS | 25,430 | 0,00 % | Biotech Stocks At 52-Week Highs - Alamar Biosciences +30% on Q2 Reports, Dyne Therapeutics, Cullinan Therapeutics, DexCom, Cardinal Health | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,840 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 135,06 | -0,02 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| VOR BIOPHARMA | 22,480 | 0,00 % | Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 349,94 | -0,10 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |
EVAXION A/S ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,33 % bei einem Aktienkurs von 3,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.